Window of Opportunity in Psoriatic Arthritis The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome. https://t.co/eUL1wzrXVt https://t.co/XSETW2zpGs

Research presented at DDW 2024 demonstrated the superiority of guselkumab over ustekinumab or placebo in 1,021 patients with moderately to severely active Crohn's disease enrolled in the phase III GALAXI 2 and GALAXI 3 trials https://t.co/HdZf24Twsq https://t.co/REeAAskpX5

No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance Annals of Internal Medicine reports a study of more than 75,000 persons screened for MGUS and found no association between AIRD and MGUS. https://t.co/cTuIWU7eoa https://t.co/78kQvBGVzs

SLE Cost of Care and Disease Activity A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity. https://t.co/Rk7SNpHaKu https://t.co/yvJ4qw1YCJ

Lille Univ Hosp study of 485 systemic sclerosis pts, found osteoporosis in 23% (18% w/ fragility Fx). OP independently linked to age (OR1.06), topoisomerase I Ab+ positivity (OR 2.22) & GC treatment (OR 4.48) https://t.co/9KN5VQnl4A https://t.co/L7RwDdzaFZ

Greek cohort study of 570 SLE pts; lupus nephritis was initial presentation in 59, w/ another 66 LN during F/U (total LN= 22%). Predictors of LN: male sex (adjHR 4.31), Dx age <26yrs (3.71), Hi dsDNA (2.48), low C3/C4 (NS 2.24) https://t.co/lGmZlBpaPq https://t.co/XLqODDTnX6

"Don't You Know Who I am?" (5.17.2024) Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis? https://t.co/oH5qdTvGY9 https://t.co/gTqIKemvOu

Australian multicenter KARAOKE RCT of 262 adults w/ Knee OA (w/ MRI effusion/synovitis) Rx w/ placebo vs , 2 g/d of krill oil showed no significant benefit in pain VAS score, −19.9 [krill oil] vs −20.2 [placebo]. https://t.co/8QSZyzIVh9 https://t.co/WbSb2gcmHb

Upside/Downside of Steroids in Lupus Nephritis A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes. https://t.co/6NR3obURAw https://t.co/YyYBg1TcYr

Disparities in SLE care: adult Medicare cohort study of 1,036 SLE pts found 39% saw a rheumatologist q 6 mos & 28% had serologic tests. Least disadvantaged quintile had higher visit-based retention, but decreased serologic testing (aOR 0.80) https://t.co/lGoriPIMqV https://t.co/JF0RWZxRoU

Best Selling US Drugs in 2023 11 Skyrizi $10.1 billion 10 Dupixent $11.5 b 9 Biktarvy $13.15 b 8 Mounjaro $13.16 b 7 Keytruda $15.4 b 6 Stelara $15.87 b 5 Jardiance $15.89 b 4 Trulicity $16.3 b 3 Eliquis $22.1 b 2 Humira $35.3 b 1 Ozempic $38.6 b https://t.co/tiEwqyTB6D https://t.co/xghijiRFtW